PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -700.58%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.19 per share when it actually produced earnings of $0.2, delivering a surprise of +116.81%.Over the last four quarters ...